ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS
Journal: Biotechnologia Acta (Vol.6, No. 4)Publication Date: 2013-08-30
Authors : Michael Sela;
Page : 16-18
Keywords : monoclonal antibodies; epidermal growth factor receptors GFR/ErbB-1 and HER2/ErbB-2; vascular endothelial growth factor (VEGF); synergy; molecular mechanisms; tumor immunotherapy.;
Abstract
History of developing synergy between monoclonal antibodies, anti-tumor activity of monoclonal antibodies against tyrosine-kinases receptors EGFR/ErbB-1 and HER2/ErbB-2 as well as growth factor VEGF in various combinations are considered in the article. There were proposed hypotheses about potential molecular mechanisms underlay synergy between monoclonal antibodies (for homo- and hetero combinations of antibodies appropriately specific for antigenic determinants on the same or different receptors). Future trends in researches necessary to deeper understanding causes of this phenomenon and perspectives for practical application of monoclonal antibodies acted synergistically as immunotherapeutic drugs for human tumors treatment are reviewed.
Other Latest Articles
- OBTAINING OF MONOCLONAL ANTIBODIES AGAINST CHOLERA TOXIN AND HEAT LABILE ENTEROTOXIN OF E. coli FOR DEVELOPMENT OF THE TOXINS DIPLEX ANALYSIS IN ENVIRONMENTAL SPECIMENS
- USAGE OF MONOCLONAL ANTIBODIES FOR DETERMINATION OF LOCALIZATION OF ANTIGENIC DETERMINANTS AND FIBRIN POLYMERIZATION SITES WITHIN FIBRINOGEN AND FIBRIN MOLECULES AND THEIR APPLICATION IN TEST--SYSTEMS FOR DIAGNOSTICS AND THE THREAT OF THROMBUS FORMATION
- IMMUNOBIOLOGY OF DIPHTHERIA. RECENT APPROACHES FOR THE PREVENTION, DIAGNOSIS, AND TREATMENT OF DISEASE
- SOME RECENT FINDINGS IN THE BIOTECHNOLOGY OF BIOLOGICALLY IMPORTANT NUCLEOSIDES
- SEARCH OF INHIBITORS OF HERPES VIRAL REPLICATION: 30 YEARS AFTER ACYCLOVIR
Last modified: 2016-11-19 01:52:32